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Objective To placebo of trans­
urethral microwave thermotherapy 
treatment of benign prostatic enlar
m
7)•
Patients and methods A prospective, randomized sham-
groups; 62% and 18% of patients had a >50% 
improvement; in symptom score in the treated and 
sham groups, respectively (P=0. ). corre-
sponding changes in flow rate were 36% and 11%
controlled study in 93
50-
TUMT or a sham tret
an age 65, range 
at two centres comparing 
. Patients randomized to
receive sham treatment underwent the same initial 
procedure as for TUMT, but the complete procedure 
was simulated on the visual display with no appli­
cation of microwave energy. If the patient’s condition 
had not improved after 3 months, a second genuine 
TUMT treatment was given at the patient’s request.
(P* 0.002), 1 63
were divided into those that had TUMT initally, those 
that had sham initially but subsequently had TUMT 
and those whose sham procedure had led to sufficient 
clinical improvement to require no further treatment. 
The two treated groups had a significant improvement 
over the sham group.
Conclusion The benefit from TUMT cannot be due to a 
placebo effect alone.
Results After 3 months there were significant clinical Keywords Benign prostatic enlargement, placebo,
and statistical differences in efficacy between the thermotherapy (TUMT)
Introduction
:al minimally invasive treatments for patients
atic benign prostatic enlargement (BPE) have
on anical
disruption or distraction of the prostatic urethra, e.g. 
balloon dilatation or stenting [1-3] but prostatic heating
appears to be the most promising alternative. Heat can 
be delivered selectively to the prostate using 
sources, e.g. high intensity focused ultrasound (HIFU), 
radiofrequency (transurethral needle ablation, TUNA), 
endoscopic lasers and microwave devices [4—8 J. So far, 
the microwave techniques have been the most exten­
sively investigated. There are two basic concepts; one is 
hyperthermia, where the prostatic temperature is not 
allowed to exceed 45T  and the 
where the target temperature is >45''0 [9-12], Initially,
is
research was concentrí use of mia
was probably ineffective in the treatment of BPE and 
thus should not to be recommended [14|.
Recently, many researchers have used a higher tem­
perature in microwave treatments, or thermo therapy. 
These treatments deliver high-power microwave energy 
deep within the lateral prostatic lobes, causing irrevers­
ible cell damage to prostatic tissue but without damaging 
the urethra. Results of transurethral microwave thermo- 
therapy (TUMT) are very promising, although the degree 
and significance of the placebo effect remains contro­
versial [15]. Reports from two other groups have sug­
gested that the response to TUMT is significantly greater 
than that due to any effect of placebo or instrumentation 
16,17]. A recent report by Nawrocki et ul. cast doubt 
on the validity of these conclusions [18].
In this paper we present the long-term results of a 
randomized placebo-controlled study conducted in two 
centres. Moreover, we give an overview of the published
delivered with either a transurethral or transrectal appl­
icator. Hyperthermia was evaluated against sham treat­
ment in a multicentre study in which five machines 
(three transrectal and two transurethral) were 
[ 13] and which concluded that transrectal hyperthermia
extent of the placebo
on TUMT and
in T
the
of
itic bladder outlet obstruction due to BPE.
A m
Patients and methods
From June 1991 to December 1992, 93 men (mean age
Accepted lor publication 12 September 1995 65 s, n 88) were recruited into the study.
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For entry into the study, all patients had to be >45 PcO.O5) while the Wilcoxon signed-rank test and the
years old and complaining of symptoms of bladder outlet Kruskal-Wallis test were used lor comparisons between
obstruction for > 3 months, have a Madsen symptom
score of > 8 and urinary lree-flow rate estimates of <15
groups. The chi-squared test was used to assess the 
significance of differences in response rate between the
mL/s during two voids of >150 mL. The presence of groups. 
BPE was confirmed by transrectal ultrasonography
(TR'US), the measurement of prostate-specific antigen 
and, where necessary, by prostatic biopsy. Exclusion
Results
criteria were: prostate cancer, prostatitis, urethral stric- There were no statistical differences between either the
ture, intravesical pathology (stones, neoplasm), neuro­
genic bladder dysfunction, urinary infection,
sham or TUMT group (Table 1). Patients from the London 
centre were significantly older, had more symptoms,
isolated enlargement of the middle lobe, a residual urine particularly ones, and a greater residual
volume of > 300 mL, use of drags influencing bladder urine volume than those at Nijmegen (Table 1). There
or prostate function, previous transurethral resection of were marginal study
the prostate (TURP) or transurethral incision, a metallic groups and those that had a re-treatment TUMT after
I
pelvic implant, disorders of blood flow or coagulation, sham treatment. Eighty-eight patients were available for
diabetes mellitus and mental incapacity or inability to assessment at 3 montlis and 63 at 1 year. The fate of
give informed consent. the other patients is given in Table 2. The period of
The assessment before treatment consisted of a general follow-up for each group is given as the time after the
history and complete physical examination. Serum creat- last treatment session, whether a first or second TUMT
inine, urea, and electrolytes and a full blood count were or sham, rather than from the beginning of the study.
measured, and urine was sent for microbiological and The 46 patients who received sham treatment experi-
cytological analysis. The severity of symptoms was enced a significant improvement in symptoms at 3
expressed by a Madsen symptom score [19]. Flow rates months, with the initial mean Madsen score of 12.9 ± 3.1
were corrected for artefacts by two independent observers decreasing to 10.4 + 4.7. However, there was no signifi
(M. H. and M.de W) using the 2-s method [20], with no cant change in the peak flow rate (Table 3). Thirteen
knowledge of the patient’s treatment. The voided volume patients were sufficiently content with their symptoms
was correlated with the post-void residual volume (PVR) that no further intervention was required by 1 year,
to give a ‘voiding fraction’, using the formula: voiding representing the best possible outcome of the sham
fraction = voided volume/(voided volume 4- PVR) [21]. treatment or the maximum placebo effect. Only the
TRUS was performed to measure the dimensions and symptom score had improved significantly from baseline.
configuration of the prostate and prostatic volume calcu The main complication was the rate of retention. After
lated using the formula of Stamey and Terris [22]. the genuine TUMT treatment, 10 patients (21.%) needed
The procedures for TUMT treatment have been a transurethral catheter, whereas in the sham group,
described previously [8]. When a patient was randomized only one patient was unable to pass urine freely.
to receive the placebo (sham) treatment, the whole Following either TUMI.1 or TUMT after a sham treat-
procedure was simulated but without applying micro- ment, there was a statistically significant improvement
wave energy. During both active and sham procedures, in both Madsen score and flow rate over baseline, at
a real-time treatment profile was displayed on the com- both 3 months and 1 year. Comparison with the sham
puter screen and explained to the patient. The sequence group at 3 months showed a significant difference in
of temperature calibration and checks were identical in outcome for each of the variables. At 1 year, the patients
both groups. At the end of the session, patients were treated by TUMT continued to have a statistically signili-
asked to remain in the department until satisfactory cant improvement over the remaining patients from the
voiding had been established. In case of retention, a sham group in both Madsen score and flow rate. The
urethral catheter was placed for 1 week. The baseline were no srences at 1 for PVR or
tests were repeated at 1, 12 and 52 weeks after treat- voiding fraction amongst the three groups.
ment. As far as possible, the patient and the investigator Stratification of the three groups by the outcome at 3
were kept unaware as to the treatment administered. months, defined by the criteria for success suggested in
When a patient noticed no improvement after 3 months, the Food and Drug Adminstration (FDA) guidelines is
whether he had previously received a sham or active shown in Table 4. There were more successful patients
treatment, a second genuine TUMT was performed on among those receiving TUMT than among those receiv-
request. ing a sham treatment when assessed by both
Statistical analysis within each group was carried out score and peak flow rate, but the difference was not as
using Student’s i-test (with significance defined as striking using the change in PVR as a criterion of success.
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Tabic 1 Differences in baseline variables between the contributing centres and in each treatment group
Age
(years)
Prostate 
volume, (till,)
Madsen
score
I'eak-Jlow
(mIJs)
PVR*
(ml,)
Voided
fraction (%)
Centre
Charing Cross
Mean 67.2 46.3 14.2 9.1 132.5 67.3
si) 8.1 18.1 3.2 2.4 72.8 15.S
Nijmegen
Mean 63.4 50.8 12.6 9.6 ^5 ) <S J.O
SI) 6.0 18.2 i.2 ) t  ^  * / 46,8 12.8
P-value 0.016 0.1 16 0.0 36 0.269 <0.001 <0.001
Treatment (no. of patients) 
Sham (4ft)
Mean 6 3.9 49.0 12.9 9.6 84.7
r*» \
/ /. 3
SI) 6.0 20.0 3.1 66.1 15.7
TIIMT (47)
Mean 6 6.3 48.6 13.7 C) 1r  * «*4 9 3.9 74.9
SI) 8.1 1 6.6 3.4 ) qé ~ t » J 75.4 16.6
TIIMT after sham (27)
Mean 65.8 52.0 13.6 9.0 1 1 0 .0 70.6
SI) 6 .1 2 3.9 2.8 3.3 80.4 17.8
P- value 0.197 0.50 3 0.435 0.385 0.259 0.9 38
PVR, Post-void residual volume
Table 2 The number of patients in all groups and the treatments 
and losses during follow-up
Im» up
Sham
Lost to follow-up 
Second TIIMT 
Other*
TIIMT
TURP
Lost lo follow-up 
Second TIIMT
Deathf
TIIMT after Sham 
Lost lo lbllow-up 
Laser 
()thcr$
Dealht
TIIMT after TUM'l 
Lost, to follow-up
Baseline
16
47
/ / 
+mt  /
4
Numbers of patients (months)
4 3
1
45
26
1
4
mm
f i
RneiM M «n
IS
if)
1
3
1
13 
3
4
12
1 3 
1
4
3 3
I
ì
1=5
f t
1
1
2
2
Technical failure.t Not related to treatment. * al -blocker treatment
Discussion
The placebo phenomenon is difficult to deline and the 
terminology in treatments using devices is still a matter 
of debate. Traditionally, placebo trials are assoek 
with drug studies and the benefits which a patient may 
experience while taking a placebo are often assumed to 
result only from the psychological improvemen t; obt ained 
by contact with those involved in the trial, or by better 
education in health matters. However, there may also 
be some improvement due to the natural resolution of 
the disease process or as a result of the interventions 
required during the study, Placebo studies do not address 
fully the problem that the natural history of the disease 
is necessarily brief, because there are ethical constraints 
against witholding treatment for a prolonged period. The 
spontaneous changes occurring in any pr
are best observed by comparing an active treatment to 
an arm with no treatment, randomly and prospectively.
A in  a pt
1
a
may seem to occur as the result of the study, e.g, an
or fromu rin e rt
repeated catheterization studies of BPK. in device-based
rece
may have a previously unsuspected therapeutic benefit,
e.g. a
(© 1996 British Journal of Urologi/ 77, 221-227
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Table 3 Main follow-up indices in the sham, TUMT and TUMT after sham groups at baseline, 12 and 52 weeks
Baseline
Follow-up at 
12 weeks
Follow-up at 
52 weeks
Mean 95% Cl Mean 95% Cl P-value Mean 95% Cl P-value
Madsen symptom score
Sham 12.9 11.9; 13.9 10.4 8.9; 11.8 0.003 8.2 5.5; 11.0 0.011
TUMT 13.7 12.7; 14.7 4.7 3.6; 5.9 <0.001 4.2 3.0; 5.3 <0.001
TUMT after Sham. 13.6 12.4; 14.8 5.4 3.6; 7.2 <0.001 7.0 3.8; 10.2 0.005
Peak flow rate (mL/s)
Sham 9.6 8.8; 10.4 9.7 8.7; 10.7 0.846 10.5 7.9; 13.1 0.657
TUMT 9.2 8.4; 9.9 13.4 11.7; 15.3 <0.001 13.4 11.6:15.1 <0.001
TUMT after Sham 9.0 7.6; 10.4 13.4 11.1; 15.7 <0.001 12.8 9.8; 5.8 0.033
Post-void residual urine (mL)
Sham 84.7 64.0; 105.1 104.1 74.7; 133.4 0.428 56.3 16.9; 95.7 0.433
TUMT 93.9 71.8; 116.0 34.2 19.4; 46.8 <0.001 49.7 33.0; 66.3 0.002
TUMT after Sham 110.0 76.9; 143.2 67.1 37.7; 91.1 0.012 57.3 23.4; 91.1 0.13 3
Voided fraction (%)
Sham 77.3 72.4; 82.1 75.4 69.6; 81.3 0.936 83.5 73.8; 93.2 0.814
TUMT 74.9 70.1; 79.8 89.5 85.2; 93.7 <0.001 84.5 79.3; 89.7 <0.001
TUMT after Sham 70.6 63.3; 77.8 81.0 73.8; 88.2 0.015 84.5 77.1; 92.0 0.116
Table 4 The proportional improvement in the main indices at 3 months of follow-up: percentages are based on intention to treat
Improvement from baseline parameter
<25% 2* 25% < 50% >  50% > 75%
Madsen symptom score
Sham 26 58% 11 24% 8 18% 4 9%
TUMT 10 21% 8 17% 29 62%
P = 0.002
14 30%
TUMT after sham 9 33% 5 19% 13 48%
P< 0.001
9 3 3 %
Peak flow rate (mL/s)
Sham 31 69% 9 20% 5 11 % 4 9%
TUMT 23 49% 7 15% 17 36%
P <0.002
12 26%
TUMT after sham 13 48% 2 7% 12 44%
P<  0.001
7 2 6 %
Post-void residual urine (mL)
Sham 31 69% 4 9% 10 22% 8 18 %
TUMT 18 38% 6 13 % 23 49%
P *  0.002
21 45%
TUMT after sham 14 52% 6 22% 7 26%
P = 0.449
5 19 %
thermotherapy. One of the critical issues for the evalu- was indeed a significant placebo/instrumental response
ation of devices for the treatment of symptomatic BPE is in patients undergoing sham treatment. The two other
whether the placebo response seen with drug studies comparisons of TUMT and sham treatment [16,17] also
can be expected with any treatment, be it a device or showed similar changes in the Madsen score in both the
even surgery. TUMT and sham arms (Fig. la). There are some differ-
The results of the present study suggest that there ences in the peak flow rate changes, in that the study
1996 British Journal of Urology 77, 221-227
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Previous studies comparing TUMT to sham agree that 
there is a greater benefit from thermotherapy [16,17].
Both par in 'sent, s
significant di
; at 3 months individually; there was a 
'e between the outcome of sham and
TUMT in both [26,27].
London[26I
b in
effect of placebo because
a in the sham-treated arm in o r i
significantly during follow-up, thereby
data. By pooling the data from these two
were carried out according to the same 
protocol, the evidence for a placebo effect is strengthened. 
Only one study has concluded that the majority of the
effect of TUMT is due to a placebo response [ 1
a nan- 
thermo-
therapy by Bdesha et a i [17] and
of
in How rate changes between sham and treatment, but 
it is presumed that this is due to the small increase in 
How rate seen application of transurethral 
microwave energy at lower power and without simul­
taneous cooling of the applicator [13,23 ]. The similarity 
of the improvement in symptom score in a non-irrigated 
method of thermotherapy, e.g. that used by Bdesha ¿’t al. 
[23] with that in the present study is interesting. To 
date, there is only one paper reporting subsequent treat­
ing. 1. a, Changes in mean Madsen sympton score, b, Changes in ment of those receiving sham treatment, and a 1-year
Baseline 3 months
mean peak How rate (mL/s). Dark green, Sham. Light red, 
TUMT.A = [ 131, B = 11 ft I, C =  Present study.
by Perrin and 
peak How at 3
: [17] s 
s and the í
(Fig. lb), 
transurethral microwave 
from
a small decline in 
by Blute et al. [ 16 
than in the present
no c
a 16% improvement 
in symptoms and a deterioration in peak How rate and 
PVR in the sham arm [23]. This result is comparable 
with the symptomatic improvement of 19% in the cur­
rent study. One of the best controlled drug studies in
;
J is that by
International Finasteride study group [ 24[, which had a 
placebo arm followed for up to 1 year 
1 54 patients. The mean change in 
was —2.6, from a baseline of 19.2,
score
Boyarski score with a maximum of 36. The increase in 
How rate was minimal, with an improvement of only 
0.4 mL/s from a baseline of 8.6 mL/s in the placebo- 
treated patients. Jardin et a l [25| reviewed the placebo
in studies of alpha-blocking agents and reported
follow-up which showed similar results to the present
[28]. However, that study comprised few patients 
microwave therapy was more in the range of
an in that of thermal therapy 
of a three-way randomization between sham, TUMT and 
watchful waiting (WW) comprising 120 patients in total 
15] reported that the WW group showed no clinically 
relevant deterioration or improvement. The sham-treated 
group had a symptomatic improvement (45%) compar­
able to TUMT (50%), There was little clinically relevant 
improvement of the objective variables in T
r jp
C no relevant improvement in the sham-treated
. However, in that study 
if they had severe obstruction, as 
(low studies, and may not t
s were selected
to at in present study (P. Nawrocki, personal 
communication). There is evidence to suggest that TUMT 
has much less effect on patients with more severe
29).
The conclusion from these comparisons of TUMT and 
sham treatment must be that there is an effect of heat 
on bladder outlet function in the older man and that
a small part of clinical benefit can be accounted
a change in How rate from —2.7 to+ 2.3 mL/s. T for by effect of placebo or ins
placebo response found in 'I 
that in many drug s
ir
patients from am to TUMT
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